HER2DX genomic test [17] is a single 27-gene expression and clinical feature-based classifier which provides two independent scores to predict both long-term prognosis and likelihood of pCR in HER2+ early breast cancer treated with trastuzumab based therapy. Here, ERBB2 is linked to breast carcinoma.